Multiple Sclerosis: Clinical Trials

3546 trials for Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1984 completed, 490 unknown, 367 recruiting, 241 terminated. 1304 Not applicable, 473 Phase 2, 312 Phase 3, 293 Phase 1, 216 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable1304Completed 713, Unknown 236, Recruiting 151, Not yet recruiting 70, Active not recruiting 56, Terminated 40, Withdrawn 19, Enrolling by invitation 16, Suspended 3
Phase 2473Completed 263, Terminated 70, Recruiting 42, Unknown 40, Withdrawn 24, Active not recruiting 17, Not yet recruiting 12, Enrolling by invitation 4, Suspended 1
Phase 3312Completed 194, Terminated 41, Active not recruiting 24, Unknown 23, Recruiting 15, Withdrawn 11, Not yet recruiting 3, Suspended 1
Phase 1293Completed 161, Terminated 34, Recruiting 33, Unknown 25, Not yet recruiting 13, Active not recruiting 12, Withdrawn 11, Enrolling by invitation 2, Suspended 2
Phase 4216Completed 131, Terminated 34, Unknown 17, Withdrawn 13, Recruiting 9, Active not recruiting 8, Enrolling by invitation 2, Not yet recruiting 2
Early Phase 134Completed 11, Recruiting 7, Not yet recruiting 5, Unknown 5, Suspended 2, Withdrawn 2, Active not recruiting 1, Terminated 1

Follow this condition Literature Review of Multiple Sclerosis trials Research Report on Multiple Sclerosis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of Vigorous Versus Low Intensity Cool Room Treadmill Training in People with Multiple Sclerosis
Body-weight supported treadmill training in a room cooled to 16°C - Multiple Sclerosis, Neurological Rehabilitation
Not applicableWithdrawnMemorial University of Newfoundland2030-01-012024-11-27
Inductive Therapeutic Exercise in Multiple Sclerosis
Experimental: Inductive Therapeutic Exercise (ETI), Control: Sham Inductive Therapeutic Exercise (sham-ETI) - Multiple Sclerosis
Not applicableNot yet recruitingFundación San Juan De Dios302027-10-012026-10-02
Exploring Reproductive Decision-Making Among Women With Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University2722027-06-012026-09-21
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
Phase 2Not yet recruitingMoein Amin202027-03-012026-08-19
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
C-CAR168 - Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Phase 1 / Phase 2Not yet recruitingAbelZeta Inc.1192027-02-012026-10-13
Exercise With and Without Cognitive Training
Effect of Exercise with and Without Cognitive Training on Gait - Multiple Sclerosis
Not applicableNot yet recruitingVA Office of Research and Development302027-01-042026-03-03
Lead Exposure and Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingAssiut University1402026-12-302026-02-20
Local Vibration and Ankle Mobilization in Multiple Sclerosis
Local Vibration, Ankle Joint Mobilization - Multiple Sclerosis
Not applicableNot yet recruitingGaziantep Islam Science and Technology University602026-12-152026-10-19
A Basket Study of CTA313 in Participants With Active Autoimmune Diseases
CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS)
Phase 1Not yet recruitingImviva Bio812026-12-012026-08-24
Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care
Cohort - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Not yet recruitingLuxembourg Institute of Health1002026-12-012026-09-22
Autologous Hematopoietic Stem Cell Transplantation for Refractory Multiple Sclerosis
Autologous haemopoietic stem cell transplantation - Multiple Sclerosis
Not applicableNot yet recruitingTianjin Medical University General Hospital202026-12-012026-10-16
Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS) - Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Not applicableNot yet recruitingUniversity of Alabama at Birmingham302026-12-012025-12-22
[18F]F-DED PET Imaging of Reactive Astrocytes in Multiple Sclerosis
[18F]fluorodeprenyl-D2 - Multiple Sclerosis
Not applicableNot yet recruitingParc de Salut Mar302026-12-012026-09-04
Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care
MS Boost, Standard of care - Multiple Sclerosis, Fatigue Syndrome, Chronic
Not applicableNot yet recruitingAd scientiam2082026-12-012025-10-03
Evaluation of an Online, On Demand Multimodal Wellness Program to Reduce Fatigue and Improve Quality of Life in Progressive Multiple Sclerosis.
Online wellness course and online exercise platform, Usual Care Group - Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS)
Not applicableNot yet recruitingUniversity of Iowa1182026-11-152026-09-28
The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis
Moderate-Intensity Continuous Training (MICT), High-Intensity Interval Training (HIIT) - Multiple Sclerosis, High-intensity Interval Training
Not applicableNot yet recruitingHacettepe University402026-11-012026-09-23
Driving Performance in Parkinson's Disease and Multiple Sclerosis Using a Driving Simulator
Standardized Driving Simulator Assessment - Parkinson, Multiple Sclerosis
Not yet recruitingUniversity Hospital Olomouc1002026-11-012026-09-09
Emerging Indications for Hyperbaric Oxygen Treatment
Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis
Phase 4Not yet recruitingJay C. Buckey Jr.1002026-11-012026-09-09
An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online
ACTION-MS website - an 8-week cognitive behavioural therapy intervention for depression., The 'Health and Wellbeing in MS' website - Depression and Anxiety Symptoms, Multiple Sclerosis
Not applicableNot yet recruitingUniversity of Melbourne2402026-11-012026-10-15
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
Cetirizine, Diphenhydramine - Multiple Sclerosis
Phase 3Not yet recruitingUniversity of Miami602026-11-012026-10-02

Showing 20 of 3546. Sign in to see all of them.

Narrower conditions

Multiple Sclerosis, Relapsing-Remitting (612)  ·  Multiple Sclerosis, Chronic Progressive (242)  ·  Fatigue (210)  ·  Motor Activity (170)  ·  Stroke (105)  ·  Parkinson Disease (97)  ·  Cognitive Dysfunction (75)  ·  Muscle Spasticity (75)  ·  Depression (70)  ·  Spinal Cord Injuries (69)  ·  Autoimmune Diseases (67)  ·  Demyelinating Diseases (66)  ·  Nervous System Diseases (58)  ·  Neuromyelitis Optica (56)

Broader conditions

Immune System Diseases (3528)  ·  Demyelinating Autoimmune Diseases, CNS (3527)  ·  Autoimmune Diseases of the Nervous System (3506)  ·  Nervous System Diseases (3488)  ·  Demyelinating Diseases (3480)  ·  Autoimmune Diseases (3479)  ·  Pathological Conditions, Signs and Symptoms (923)  ·  Signs and Symptoms (537)  ·  Pathologic Processes (439)  ·  Disease Attributes (364)  ·  Chronic Disease (295)  ·  Behavior (291)  ·  Central Nervous System Diseases (286)  ·  Neurologic Manifestations (265)

Interventions

Interferon beta-1a (106)  ·  ocrelizumab (82)  ·  Dimethyl Fumarate (70)  ·  Exercise (70)  ·  Natalizumab (66)  ·  Interferon beta-1b (64)  ·  Fingolimod Hydrochloride (57)  ·  Glatiramer Acetate (55)  ·  teriflunomide (40)  ·  4-Aminopyridine (32)  ·  Blood Specimen Collection (32)  ·  Methylprednisolone (32)  ·  ofatumumab (32)  ·  Rituximab (31)  ·  Alemtuzumab (30)

Sponsors

Biogen (160)  ·  Novartis Pharmaceuticals (92)  ·  Merck KGaA, Darmstadt, Germany (49)  ·  Bayer (47)  ·  Hasselt University (34)  ·  Hoffmann-La Roche (34)  ·  Kessler Foundation (32)  ·  Fondazione Don Carlo Gnocchi ETS (30)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (30)  ·  Sanofi (30)  ·  Johns Hopkins University (28)  ·  University of Washington (28)  ·  Gazi University (27)  ·  NYU Langone Health (26)  ·  Assiut University (25)

Countries

United States (1280)  ·  France (412)  ·  Italy (325)  ·  Turkey (Türkiye) (315)  ·  Germany (303)  ·  Canada (283)  ·  United Kingdom (283)  ·  Spain (253)  ·  Belgium (178)  ·  Poland (173)  ·  Czechia (160)  ·  Switzerland (160)  ·  Russia (120)  ·  Netherlands (115)  ·  Denmark (111)

Top investigators

Daniel S Reich, M.D. (11)  ·  Cagla Ozkul (9)  ·  Peter Feys, prof. dr. (9)  ·  Eric Thouvenot (8)  ·  John F Foley, MD (8)

Results publications

PMID 31072380, PMID 21387374, PMID 33023488, PMID 32447743, PMID 34882037, PMID 23669008, PMID 25475413, PMID 27411694, PMID 27733070, PMID 29275977, PMID 30918100, PMID 31654272, PMID 31762387, PMID 32710396, PMID 36163349, PMID 37652990, PMID 37745914, PMID 39935588, PMID 40258203, PMID 40756531, PMID 40966534, PMID 42328798, PMID 6685237, PMID 12525714, PMID 22622860, PMID 23531349, PMID 24131282, PMID 25245812, PMID 26932146, PMID 28002679, PMID 28002688, PMID 28825348, PMID 30144037, PMID 31675266, PMID 32426039, PMID 32539719, PMID 33414927, PMID 34035833, PMID 34376508, PMID 34378446, PMID 35003076, PMID 36619856, PMID 37272540, PMID 39251561, PMID 42368888, PMID 42624921, PMID 7613530, PMID 10022678, PMID 11955556, PMID 12542793

NIH funding

2014 (19), 2015 (19), 2023 (19), 2016 (14), 2018 (14), 2017 (13), 2009 (12), 2019 (12), 2008 (11), 2025 (8), 2005 (5), 2004 (3), K23AT004433 (2), K24AT012644 (2), P30DK056336 (2)